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Purpose: The intraaortic balloon pump (IABP) is useful in the treatment of failing hearts. 
Although most experience with IABPs has been with acute short-term use, the safe 
duration of therapy and possible complications of long-term IABP use are uncertain. We 
evaluated the feasibility, management, and complications associated with long-term 
IABP therapy. 
Methods: Fifty consecutive patients with 87 IABPs were evaluated retrospectively. All 
patients had IABP support for greater than 72 hours. Results and complications were 
evaluated. 
Results: The mean duration f IABP support was 23.2 days. There were 21 IABP-related 
complications in 16 patients: (16 ischemic, three infections, two hemorrhage). The rate 
of complications was 0.13 per patient-week of support. Significant predictors of compli- 
cations were total days of IABP support (p < 0.0001), use of multiple IABPs (p < 
0.0001), and attempted but unsuccessful percutaneous insertions (p < 0.001). Compli- 
cations led to 14 vascular procedures (five patch angioplasties, four bypass procedures, 
two major amputations, one fasciotomy, one groin exploration for hemorrhage, and one 
removal of an infected Dacron patch). Percutaneous removals had a 14% complication 
rate compared with none after operative removal (p = 0.02). Thirty-two patients urvived 
(64%). Of the survivors, 27 underwent transplant. 
Conclusions: Prolonged IABP therapy is feasible and is associated with an acceptable rate 
of complicatious. Operative removal is superior to percutaneous removal. Percutaneous 
removal should be limited to short-term therapy. There is no need for mandatory 
removal or site rotation based solely on indwelling time. (J Vasc Surg 1997;26:511-6.) 
Intraaortic balloon counterpulsation therapy was 
first used clinically in 1967~; it has since become a 
mainstay in the treatment of heart failure. The most 
common indications for balloon pump support are 
heart failure after myocardial infarction, during sur- 
gery in cardiac bypass patients, and in patients with 
severe heart disease who are undergoing noncardiac 
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procedures. Use ofintraaortic balloon pump (IABP) 
therapy in these cases is usually short-term, and man- 
agement is clirected toward rapid removal as the 
indications for placement are resolved. The increas- 
ing demand for cardiac transplantation accompanied 
by donor shortages has created a select population of  
patients who require prolonged IABP therapy. Wait- 
ing times may be prolonged for eren the sickest 
patients. At our institution, IABP therapy is used 
regularly in severe refractory heart failure. We exam- 
ined the outcome and vascular implications of long- 
term IABP therapy and assessed the factors that con- 
tribute to complications in this group. 
MATERIALS  AND METHODS 
During the 2-year period January 1993 to March 
1995, 450 patients underwent placement of  IABP 
devices at out institution. Of  these, 50 patients were 
identified as having therapy that lasted longer than 
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72 hours and were all potential candidates for cardlac 
transplantation. 
This study is a retrospective r view of all records 
that pertain to the hospitalization and treatment of  
these 50 patients. Acquired data included patient 
demographics, associated comorbidities, and cardio- 
vascular isk factors. Data related to IABP therapy 
included the total duration oftherapy, the number of  
IABP devices per patient, indications for insertion, 
environment of insertion (operating room, cardiac 
catheterization laboratory, bedside), complications 
related to IABP therapy, and their management. In
addition, the reasons for removal, type of removal 
(operative vs percutaneous removal), and ultimate 
patient outcomes were obtained. Unsuccessful at- 
tempts at placement were also recorded. An unsuc- 
cessful attempt was defined as initial access of the 
artery with inability to pass the IABP device into 
position. 
Patients were anticoagulated with intravenous 
heparin to maintain an activated partial thromboplas- 
tin time (aPTT) of 2 to 2.5 times normal while IABP 
devices were in place. Blood samples for testing 
aPTT were initially obtained every 6 hours and were 
adjusted accordingly. When a steady stare was 
achieved, aPTT was checked daily. Patients did not 
receive antibiotics prophylactically. The adequacy or 
excess of the anticoagulation medication as it per- 
tained to complications was assessed by analyzing the 
aPTT values for the 3 days preceding and the day of 
said complication. 
Initiation of IABP support was by percutaneous 
insertion either in the cardiac atheterization labora- 
tory or at the bedside. In cases in which multiple 
IABPs were requlred, removal of the indwelling 
IABP and subsequent insertion of a new device oc- 
curred either in surgery or the catheterization labo- 
ratory. Decisions regarding removal of  IABPs and 
the method of removal (operative vs percutaneous) 
were made at the discretion of the attending physi- 
cian. Percutaneous removals were performed at the 
bedside or in the catheterization laboratory. Pressure 
was held for at least one halfhour, and longer when 
persistent bleeding occurred. In cases in which isch- 
emia occurred subsequent to removal or pulses were 
believed to be diminished, angiography was used at 
the attending physician's discretion. In all operative 
removals, a thrombectomy catheter was passed prox- 
imally and distally for removal of thrombotic mate- 
rial. Assessment of pulses (or Doppler flow) was 
performed in the operating room, and angiography 
was used when indicated. 
Complications were classified as ischemia, hein- 
orrhage, local infection, and general sepsis. Ischemia 
was defined as one or more of the following: objec- 
tive documentafion fa disappearänce or decrease of 
pulses, skin changes uch as mottling, cyanosis, or 
decreased temperature, or evidence of emboli. In 
addition, assignment ofischemia required that either 
removal of the IABP or a vascular procedure was 
needed for correction. Hemorrhage was defined as a 
significant bleeding episode that necessitated an op- 
erative procedure for control, removal of the LABP, 
or transfusion. Local infections were defined as puru- 
lence from the wound or positive deep wound cul- 
tures. Cellulitis was also considered a local infection. 
Sepsis was defined as a positive blood culture with 
the säme organism being cultured from the IABP 
infection site and clinical suspicion of the IABP as the 
source. Complicafions were recorded individually 
and, in addition, were stratified as ischemic vs other 
(hemorrhage, sepsis, local infection). The rate of 
complications was recorded as per week of IABP 
support. 
Thirty-one. independent variables were evaluated 
as possible predictors of complications. StatView 
software Macintosh version 4.5 (Abacus, Berkeley, 
Calif.) was used for statistical analysis. Differences 
between categoric variables were assessed using the 
X 2 or Fisher's exact est. An unpaired Student's t test 
was used to define differences between continuous 
variables in subgroups. Statisfical significance was 
assumed at ä p value less than 0.05. Variables found 
to be stäfisfically significant were subjected to multi- 
variate and stepwise logistic regression analysis. 
RESULTS 
The 40 men and !0 women included in this study 
had an average age of 56 yeärs (fange, 32 to 77 
years). Diabetes that required insulin was present in 
12 patients (24%). TwentT-eight patieuts (56%) had 
a history of hypertension. Only one patient had a 
history of peripheral vascular disease. Mild renal in- 
sufficiency (defined as a serum creatinine level >1.5 
mg/dl)  was present in 37 patients (74%). The pa- 
fients' averäge serum creafinine level was 1.9 mg/dl.  
Renal function improved in 17 of these pafients 
(46%) with insfitufion ofIABP therapy. The cause of 
heart failure was ischemic ardiomyopathy in 36 pa- 
tients (72%), idiopathic ardiomyopathy in six (12%), 
acute myocardial infarction in five (10%), chronic 
rejection of  heart allograft in one (2%), hypertensive 
cardiomyopathy in one (2%), and ethanol-induced 
cardiomyopathy in one (2%). In all patients, echocar- 
diogräphy was performecl luring the hospitalizafion 
under study. The average jection fracfion, by echo- 
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cardiography, was 18.7% (median, 17.5). All patients 
were New York Heart Association class IV. 2 
A total of 89 IABPs were used, with successful 
placement of 87 (98%). The indication for initial 
insertion in all patients was an inability to malntain 
sutficient cardiac output despite maximal pharmaco- 
logic support. The average duration of support was 
23.2 days (range, 3 to 89 days). The average dnra- 
tion for any one IABP was 13 days. A percutaneous 
method ofinsertion was used in 67 of the procedures 
(77%). Twenty-three percent (20 IABPs) were 
placed by an open operative technique. Two patients 
had one unsuccessful attempt at percutaneous inser- 
tion with subsequent successful placement in the 
contralateral femoral artery. In both cases this was 
during the first attempt o establish IABP support. 
All percutaneous insertions Were in the femoral ar- 
tery. Operative insertions were in the common fem- 
oral artery in all but two cases, one ofwhich used the 
iliac artery and the other the superficial femoral ar- 
tery. Of the percutaneous insertions, 36 (54%) were 
performed at the bedside in a critical care setting. 
The others were placed in the cardiac atheterization 
suite. Removal was by a percutaneous method in 28 
cases and open operative removal in 48, and 11 
IABPs were in place at the time of patient death. 
A total of 21 IAßP-relatecl complications oc- 
curred in 16 patients (32%). Ischemic omplications 
were the most frequent, with 16 distinct episodes in 
12 patients (24%). Other complications included 
sepsis in three patients, one of whom also had an 
ischemic omplication, and two cases ofhemorrhage, 
one requiring operative intervention and one requir- 
ing removal of the IABP. Five of these complications 
(24%; four ischemic, one hemorrhage) occurred at 
the time of insertion. Twelve (57%; eight ischemic, 
threc septic, one hemorrhage) occurred during 
maintenance, and four (all ischemic) occurred at the 
time ofremoval. Complications that occurred at time 
ofinsertion »vere resolved with removal of the IABP. 
The one hemorrhagic complication that occurred at 
the time of insertion was a result of a perforation of 
the external iliac artery during percutaneous place- 
ment and required operative repair. Ischcmic ompli- 
cations that occurred uring maintenance and at the 
time of removal were all thrombotic or embolic in 
nature. In all but one case (treated by thrombolysis) 
these required operative intervention. In most cases 
thrombectomy/embolectomy with patch angio- 
plasty was sufficient to relieve ischemia. In four cases, 
bypass procedures were performed. Three of the pa- 
tients with ischemic complications required lower 
extremity amputation: one above-knee amputation, 
Table I. Factors causing use of multiple 
intraaortic balloon pumps 
Reason for removal No. of occurrences 
Mechanical malfunction or ruptur,e 14 
Isch+mia 10 
Failed wcaning 5 
Ble¢ding 2 
Confirmed sepsis 2 
Possible source of  fever 2 
Removed at timc of  cardiac 1 
cathetcrization 
one below-knee amputation, and one toe amputa- 
tion. All ischemic omplications that resulted in am- 
putation occurred during maintenance therapy. 
When considering the extended nature of therapy, 
the rate of complications was 0.13 complications per 
week of therapy. 
The 12 patients who experienced ischemic om- 
plications had a total of 34 successfully placed IABPs 
(range, 1 to 7). The duration of treatment in this 
group averaged 37.6 days (range, 10 to 89 days) 
compared with 18.6 days for patients without isch- 
emic complications (p < 0.0001). Excluding the 
IABPs that caused ischemia immediately after inser- 
tion (n = 4), these complications occurred on aver- 
age 22 days from the time ofinsertion. Two of these 
patients had unsuccessful attempts at percutaneous 
insertion, which required placement in the contralat- 
eral femoral artery. Ischemia later developed in both 
of these patients in the limb ipsilateral to the unsuc- 
cessful attempt (p < 0.001). The four episodes of 
ischemia that occurred at the time of removal or 
shortly thereafter (25% of total ischemic episodes) 
were all in cases in which the IABP was removed by a 
percutaneous method (at day 3, 7, 8, and 79). No 
episodes ofischelnia occurred after operative removal 
of the IABP. This was statistically significant (p = 
0.02). 
Multiple IABPs (n = 56) were used in 19 pa- 
tients. Thirty-six of these IABPs required removal 
and replacement (Table I). Twenty were removed as 
support was weaned or the patient expired. Nine of 
the 12 (75%) patients in the ischemic group had 
multiple IABPs, compared with 10 of 38 (26%) in 
the group without ischemic complications (p < 
0.0001). Reasons for removal/replacement were 
IABP rupture or malfunction (14), ischemia (10), 
failed weaning (5), sepsis (2), bleeding (2), as a 
possible source of fever (2), and removal and replace- 
ment at the time of cardiac atheterization (1). 
Fourteen major vascular procedures were per- 
formed (Table II). These included five patch angio- 
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Table II. Surgical procedures resulting from 
vascular complications 
Surgical procedures No. 
Thrombectomy and patch angioplasties 5 
Major amputations 2 
Ileofemoral bypass 1 
Axillofemoral bypass 1 
Femorofemoral bypass 1 
Femoropopliteal bypass 1 
Fasciotomy 1 
Groin exploration for hemorrhage 1 
Removal infected Dacron patch 1 
plasties, four bypass procedures, two amputations, 
one fasciotomy, one exploration for hemorrhage, 
and one removal of an infected Dacron patch. Patch 
material was saphenous vein in four instanccs and 
Dacron in one. The Dacron patch required eventual 
removal because of infection. In addition to these 
procedures, 29 IABPs were removed by oPeration 
with thrombectomy and primary repair. 
Thirty-two patients urvived (64%) and were dis- 
charged from the hospital. Twenty-seven of the pa- 
tients (54%) underwent successful orthotopic heart 
transplantation. No deaths were directly related to 
IABP complications. Heparin-induced thrombocy- 
topenia ssociated with anticoagulation during IABP 
use did contribute to one patients' demise. 
Statistical analysis of the 31 independent variables 
revealed only four as being significant in affecting the 
rate ofischemic omplications. These were total days 
ofIABP therapy (p < 0.0001), use ofmultiple IABPs 
(p < 0.0001), and the ipsilateral occurrence of an 
unsuccessful attempt at percutaneous insertion (p < 
0.001). Patients who underwent percutaneous re- 
moval were also more likely to have ischemic ompli- 
cations (p = 0.02). 
D ISCUSSION 
Prcviously published series, a-Is in which IABP 
use was ptimarily short-term, havc also found that 
ischcmic omplications wcrc the most frequently en- 
countcrcd. Many of the published series had an aver- 
agc duration of IABP use of 1.5 to 2 days, and the 
total rate of complications was 6% to 25%, with most 
being on the lower end2 -16 In scrics in which IABPs 
wcrc uscd for a longcr timc (mcan, 8 to 11 days), 17,18 
the rate of ischemic omplicätions was bctwcen 19% 
and 22%, which agrees with our findings that longcr- 
term support is associated with an incrcased inci- 
dcncc ofisehcmia. Howcvcr, our rcsults suggcst hat 
thc initial arterial trauma may be an important factor 
in the pathogenesis of ischemia nd that indwelling 
devices are less likely to precipitate sudden ischemia. 
In this study 50% of the ischemic complications 
occurred at the time of insertion or removal. Harvey 
et al. 4 noted a similar finding, with 25% of ischemic 
complications occurring immediately on insertion. 
Many series have noted a high rate of dissection at 
insertion, which can cause immediate symptoms or 
symptoms at removal. 3,7,19 Unsuccessful attempts at 
insertion as a result of preexisting arterial disease, 
hasty insertion at time of patient duress, or multiple 
balloon insertions were also associated with more 
frequent complications. As a result of mechanical 
failure or balloon complication, many of our patients 
with prolonged IABP support had several balloons 
inserted uring the course of their treatment. 
The ratio of the femoral artery size to the balloon 
size has been implicated as a causative factor in arte- 
rial occlusion. Women, who generally have smaller 
arterial umens, and patients with significant ath- 
erosclerotic occlusive disease have been noted by 
other authors to have more ischemic complica- 
t ions, s's'6,9-11 Mthough we did not note an anatomic 
cause for ischemic omplications, we did see a trend 
of fewer complications in the smaller diameter, 
sheathless balloons (/9 = 0.07). Tatar et al) 4 also 
found less ischemia with the sheathless IABP system. 
We did not find that a history of peripheral vascular 
disease was associated with ischemic problems; this 
was likely because of the nature of the disease of our 
patients and because we had to diagnose peripheral 
vascular disease retrospectively. These patients all 
had severe heart failure, and therefore lower extrem- 
ity occlusive disease would not likely be symptomatic 
when present unless it was severe. 
Our findings do indicate that long-term IABP 
support is associated with an increased incidence of 
ischemic complications. This is likely as a result of 
chronic endothelial damage, accumulation ofthrom- 
botic material, or chronic reductions of inflow to 
marginally perfused limbs. An interesting aspect of 
the timing ofischemic omplications was the chister- 
ing of events at the time ofinsertion and removal. In 
all of the patients in whom ischemia followed re- 
moval, a percutaneous removal method was used. 
Ischemia may have been prevented in these cases by 
an operative removal and thrombectomy. Rohrer et 
al. 2° addressed the safety of percutaneous removal 
and concluded that most IABP devices may be safely 
removed percutaneously when the method of inser- 
tion was also percutaneous and a bleeding diathesis 
was not present. The mean duration of therapy in 
that study was 2 days; in this study, the complications 
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subsequent to percutaneous removal fol lowed longer 
durat ions o f  therapy. Based on our experience we 
would  recommend operative removal for indwell ing 
times greater than 3 to 5 days. 
CONCLUSION 
Use o f  an IABP is a feasible method o f long- term 
mechanical cardiac support.  A l though pro longed use 
is associated with an increased risk o f  ischemic com- 
plications, the incidence o f  these complicat ions is 
acceptable considering the severity o f  the illness and 
the effectiveness o f  the treatment.  Rout ine removal 
o f  IABP devices based solely on t ime o f  inserfion 
should not  be standard when ongo ing support  is 
needed, as many complications occur at the t ime o f  
insertion and removal. Rout ine site rotat ion should 
not  be per formed despite a l imited number  o f  pa- 
tients in whom problems developed. We believe that 
operative removal is the opt imal method to prevent 
postremoval  ischemic compfications and should be 
used in all cases o f  extended use. Based on prior 
studies, percutaneous removal is probably  safe in 
patients who have a shorter durat ion o f  therapy. 
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D ISCUSSION 
Dr. Robert B. Smith I I I  (Atlanta, Ga.). Dr. Manord 
and his coauthors are to be commended for their expert 
care of an impressive group of patients with life-threaten- 
ing cardiac failure who required prolonged intraaortic bal- 
loon counterpulsation. That almost two thirds of their 
desperately sick patients urvived the hospital stay, during 
which 88% of the survivors required cardiac transplanta- 
tion, is clear testimony to superior cardiac and vasctflar 
JOURNAL OF VASCULAR SURGERY 
516 Manord et al. September 1997 
surgical care. It is interesting that during recent similar 
periods oftime, Emory University Hospital and the Osch- 
ner Clinic had equivalent numbers of patients who re- 
quired intraaortic balloon support, 404 in our case and 450 
in theirs, although they had a larger proportion with the 
device in place for durations longer than 3 days, yielding 
the subjects for this presentation. In our experience, 9% of 
patients at risk required surgical correction for vascular 
complications, and in their longer-duration group, 28% 
did. The types of complications observed and the variety of 
surgical procedures performed were very similär in both 
reviews and were generally successfully managed, although 
major amputations were required in a small number of 
patients in both series. 
It has been our experience that these patients can test 
the ingenuity and perseverance of the vascular surgeon on 
occasion. When one is called to deal with an ischemic limb 
in a patient on the pump, it may be as simple as observing 
the leg while the balloon device is promptly removed. In 
most cases that will allow adequate return of peripheral 
circulation and no fu~her intervention is required. How- 
ever, in some situations, the patient is totally dependent on 
the pump and there is no likelihood that it will be able to 
be removed in time to salvage the limb at risk. In those 
patients, we usually perform a femorofemoral extraana- 
tomic bypass procedure, provided flow is sufficient in the 
proposed onor limb. I would like to make just one tech- 
nical point here. It is my preference to construct the cross- 
over graft in an end-to-end fashion on the recipient side, to 
isolate access of the balloon catheter f om the downstream 
limb circulation, and thus to minimize the possibility of 
thrombosis or embolization on that side when the balloon 
is eventually withdrawn. I would be interested to know 
whether the authors have used this arrangement for revas- 
cularization extraanatomically. The Oschner group has ad- 
vocated operative removal of intraaortic balloons when the 
device has been in place for more than 3 days, in the effort 
to reduce thrombotic complications. That is probably 
good advice, but I would be interested to know whether 
they have been able to convince their cardiology colleagues 
of the need for this precaution? Also, in this era offrequent 
percutaneous insertions of counterpulsation balloons, is it 
cost-effective to take a sizable number of such patients to 
the operating room for open surgical removal? 
Dr. Jeffrey D. Manord. Thank you, Dr. Smith. With 
regards to your first question, we did have one patient in 
whom a proximal igation was performed with crossover 
femorofemoral bypass grafting to isolate the vascular access 
site for the balloon pump. As you noted, these patients 
require ongoing pump therapy, and on occasion we re- 
move the device and select a new site. With regards to your 
second question, the cardiologists in general are more than 
happy for us to remove these devices. They do not like to 
deal with possible complications and in most cases call us 
ahead of time so that elective operative removal can be 
planned for devices in place for extended periods. With 
regards to the cost-effectiveness, this was not specifically 
analyzed. However, these are very sick patients, and 
dealing with the cost associated with an ischemic com- 
plication can be very high. We remove these under a 
local anesthetic with sedation. The operating room time 
involved in removing these devices is generally less than 
an hour. 
Dr. Will iam M. Blackshear, Jr. (Largo, Fla.). In your 
group ofpatients who underwent percutaneous placement, 
I wonder whether you had an opportunity to look at the 
site ofentry of the device? In the patients we have operated 
on for ischemic omplications, we noted fairly frequently 
that the device entered the superficial femoral, rather than 
the common femoral artery, and that may be a point that 
would argue for operative placement of a higher percent- 
age of these devices. 
Dr. Manord. In most cases that information was un- 
available. However, this situation was noted at the time of 
operative removal in some of the patients who had isch- 
emic complications. As all of the percutaneous insertions 
were in the femoral region, this probably did contribute in 
some of the complications. 
